Aptose Biosciences Inc. Company Review & Valuation

Latest Price

About Aptose Biosciences Inc.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada.

The company's clinical programs is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

It has an agreement with CrystalGenomics, Inc.

to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in late preclinical development stage for the treatment of patients with relapsed/refractory acute myeloid leukemia and having B-cell malignancies.

The company also has an agreement with Ohm Oncology for development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules.

The company was formerly known as Lorus Therapeutics Inc.

and changed its name to Aptose Biosciences Inc.

in August 2014.

Aptose Biosciences Inc.

was founded in 1986 and is headquartered in Mississauga, Canada.

HQ Location
Mississauga, Canada

Stock Price

Price data not available for Aptose Biosciences Inc..


Please login or create a free account to view the contents of this section.

Financial Reports

Please login or create a free account to view the contents of this section.

Similar Companies

back to top


Valuu provides insights and tools for self-directed stock investors. It enables you to easily find, valuate and track your stock investments with the help of reliable financial data and transparent analysis tools.

Disclaimer: This website is a data portal, which aggregates information about public companies. It is not a stock broker and does not give advice concerning specific investment decisions or tax or legal advice. All data is provided "as-is" with no guarantee for correctness and/or completeness. All company names, logos, and brands are intellectual property of their respective owners. The use of them is for editorial purposes only and does not imply any affiliation or endorsement.
© 2019-2022 Valuu Analytics Sàrl